IQVIA Holdings Inc (IQV)vsMedpace Holdings Inc (MEDP)
IQV
IQVIA Holdings Inc
$165.64
-0.27%
HEALTHCARE · Cap: $28.11B
MEDP
Medpace Holdings Inc
$466.80
+1.32%
HEALTHCARE · Cap: $13.08B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 545% more annual revenue ($16.31B vs $2.53B). MEDP leads profitability with a 17.8% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.97. IQV earns a higher WallStSmart Score of 72/100 (B).
IQV
Strong Buy72
out of 100
Grade: B
MEDP
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$348.46
Current Price
$165.64
$182.82 discount
Margin of Safety
+40.8%
Fair Value
$716.04
Current Price
$466.80
$249.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 21 in profit
Growing faster than its price suggests
Earnings expanding 23.6% YoY
Every $100 of equity generates 70 in profit
Revenue surging 32.0% year-over-year
Strong operational efficiency at 21.6%
Earnings expanding 26.9% YoY
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Revenue Growth, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 21.6%. Revenue growth of 32.0% demonstrates continued momentum.
Bear Case : IQV
The primary concerns for IQV are Altman Z-Score.
Bear Case : MEDP
The primary concerns for MEDP are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
IQV profiles as a value stock while MEDP is a growth play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.46 — expect wider price swings.
MEDP is growing revenue faster at 32.0% — sustainability is the question.
IQV generates stronger free cash flow (561M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (72/100 vs 70/100) and 10.3% revenue growth. MEDP offers better value entry with a 40.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?